Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
$4.26
$4.23
$2.06
$4.50
$370.71M1.181.55 million shsN/A
Evotec AG stock logo
EVO
Evotec
$3.69
$4.13
$2.84
$5.64
$1.31B1.66137,086 shs28,188 shs
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
$11.52
+0.0%
$8.88
$5.79
$11.78
$1.83B1.431.44 million shs292,464 shs
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
$17.65
-1.1%
$15.61
$8.91
$18.90
$1.74B0.91.35 million shs89,690 shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
0.00%0.00%0.00%+5.45%+65.12%
Evotec AG stock logo
EVO
Evotec
-13.38%-10.44%-1.86%-7.05%-21.49%
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
+1.68%+2.22%+41.70%+45.64%+46.75%
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
-0.39%-0.28%+12.97%+19.00%+69.35%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
0.3866 of 5 stars
1.20.00.04.20.60.00.0
Evotec AG stock logo
EVO
Evotec
2.0734 of 5 stars
3.24.00.00.01.70.00.6
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
3.6424 of 5 stars
3.52.00.04.10.62.50.0
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
3.0677 of 5 stars
3.61.00.00.02.84.20.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
2.33
Hold$4.331.72% Upside
Evotec AG stock logo
EVO
Evotec
2.40
Hold$5.9360.79% Upside
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
3.00
Buy$17.3350.41% Upside
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
3.17
Buy$31.0075.64% Upside

Current Analyst Ratings Breakdown

Latest CKPT, EVO, SPRY, and OCUL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/29/2025
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00
5/15/2025
Evotec AG stock logo
EVO
Evotec
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
5/6/2025
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $14.00
4/24/2025
Evotec AG stock logo
EVO
Evotec
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSell ➝ Hold
(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
$41K9,041.59N/AN/A($0.47) per share-9.06
Evotec AG stock logo
EVO
Evotec
$862.40M1.52N/AN/A$2.91 per share1.27
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
$59.65M30.78N/AN/A$2.01 per share5.73
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
$89.15M19.44N/AN/A$2.64 per share6.69
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
-$51.85M-$1.29N/AN/AN/AN/A-659.07%8/11/2025 (Estimated)
Evotec AG stock logo
EVO
Evotec
-$212.18MN/A0.00N/AN/A-26.34%-21.51%-10.54%8/13/2025 (Estimated)
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
-$193.51M-$1.15N/AN/AN/A-323.09%-59.92%-41.98%8/6/2025 (Estimated)
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
$8M-$0.16N/AN/AN/A-16.11%-6.94%-5.60%8/5/2025 (Estimated)

Latest CKPT, EVO, SPRY, and OCUL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2025Q2 2025
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
-$0.02N/AN/AN/A$7.28 millionN/A
8/6/2025Q2 2025
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
-$0.35N/AN/AN/A$13.12 millionN/A
8/5/2025Q2 2025
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
-$0.42N/AN/AN/A$12.92 millionN/A
5/14/2025Q1 2025
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
-$0.35-$0.35N/A-$0.35$7.48 million$7.97 million
5/13/2025Q1 2025
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
-$0.10-$0.19-$0.09-$0.19$4.53 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
N/AN/AN/AN/AN/A
Evotec AG stock logo
EVO
Evotec
N/AN/AN/AN/AN/A
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
N/AN/AN/AN/AN/A
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
N/A
0.29
0.29
Evotec AG stock logo
EVO
Evotec
0.46
2.03
1.93
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
0.26
10.22
10.14
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
0.30
11.00
10.74

Institutional Ownership

CompanyInstitutional Ownership
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
22.00%
Evotec AG stock logo
EVO
Evotec
5.81%
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
59.21%
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
68.16%

Insider Ownership

CompanyInsider Ownership
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
2.10%
Evotec AG stock logo
EVO
Evotec
N/A
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
2.30%
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
33.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
1087.02 million47.81 millionOptionable
Evotec AG stock logo
EVO
Evotec
4,827355.11 millionN/ANot Optionable
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
230159.30 million155.64 millionOptionable
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
9098.21 million65.31 millionOptionable

Recent News About These Companies

ARS Pharmaceuticals: 'Betting On The Come'

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Checkpoint Therapeutics stock logo

Checkpoint Therapeutics NASDAQ:CKPT

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

Evotec stock logo

Evotec NASDAQ:EVO

$3.69 0.00 (0.00%)
As of 11:09 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Ocular Therapeutix stock logo

Ocular Therapeutix NASDAQ:OCUL

$11.52 +0.00 (+0.03%)
As of 11:11 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

ARS Pharmaceuticals stock logo

ARS Pharmaceuticals NASDAQ:SPRY

$17.65 -0.20 (-1.12%)
As of 11:11 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.